Abstracts tagged "intravenous immunoglobulin (IVIG) and vasculitis"

Abstract Number: 887 • 2015 ACR/ARHP Annual Meeting
Intravenous Immunoglobulin As Immunomodulating Agent in ANCA-Associated Vasculitides: A French Nationwide Study of 92 Patients
Etienne Crickx¹, Irène Machelart², Estibaliz Lazaro³, Jean-Emmanuel Kahn⁴, Fleur Cohen⁵, Thierry Martin⁶, Alexandre Mania⁷, Pierre-Yves Hatron⁸, Gilles Hayem⁹, Claire Blanchard-Delaunay¹⁰, Claire De Moreuil¹¹, Guillaume Le Guenno¹², Frédéric Vandergheynst¹³, Francois Maurier¹⁴, Bruno Crestani¹⁵, Robin Dhote¹⁶, Nicolas Martin Silva¹⁷, Yann Ollivier¹⁸, Anas Mehdaoui¹⁹, Bertrand Godeau²⁰, Xavier Mariette²¹, Jacques Cadranel²², Pascal Cohen²³, Xavier Puéchal²³, Claire Le Jeunne²⁴, Luc Mouthon²⁵, Loïc Guillevin²⁶ and Benjamin Terrier²³, ¹Internal Medicine, Cochin Hospital, Paris, France, ²Hôpital Pellegrin, Pessac, France, ³Hôpital Haut-Lévêque, Pessac, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine Dpt 2, Pitié-Salpêtrière Hospital, APHP, Paris, France, ⁶Cnrs UPR9021, IBMC, Strasbourg, France, ⁷Hôpital Gabriel Montpied, Clermont-Ferrand, France, ⁸Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ⁹Hôpital Ambroise Paré, Boulogne Billancourt, France, ¹⁰Internal Medicine, Centre Hospitalier, Niort, France, ¹¹CHU, Brest, France, ¹²Internal Medicine department, Clermont-Ferrand, France, ¹³Hôpital Erasme, Bruxelles, Belgium, ¹⁴HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ¹⁵Pneumology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, ¹⁶Internal Medicine, Hospital Avicenne, Bobigny, France, ¹⁷CHU Caen, caen, France, ¹⁸Hôpital Cote de Nacre, Caen, France, ¹⁹Hôpital Eure Seine, Evreux, France, ²⁰Henri Mondor, Créteil, France, ²¹Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ²²Hôpital Tenon, Paris, France, ²³Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²⁴Department of Internal Medicine, Hotel-Dieu Hospital, AP-HP, Paris, Paris, France, ²⁵Department of Internal Medicine, Department of Internal Medicine, Cochin Hospital, Referent Center for Necrotizing Vasculitis and Systemic Sclerosis, Paris-Descartes University, AP-HP, Paris, France, ²⁶Internal Medicine, Hopital Cochin, Paris, France
Background/Purpose: Despite recent therapeutic advances in treating ANCA-associated vasculitides (AAVs), some patients relapse or require long-term immunosuppression, leading to significant morbidity and mortality. IVIg represents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].